View More Recent Stories
-
PTC Therapeutics (PTCT): FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
-
TD Cowen Reiterates Hold Rating on PTC Therapeutics (PTCT)
-
Baird Starts PTC Therapeutics (PTCT) at Outperform
-
PTC Therapeutics (PTCT) ATM March 34 calls active
-
PTC Therapeutics (PTCT) PT Raised to $33 at TD Cowen
-
PTC Therapeutics (PTCT) Submits Sepiapterin NDA Submission to FDA
-
PTC Therapeutics (PTCT) Receives Negative CHMP Opinion on Translarna
-
PTC Therapeutics (PTCT) PT Raised to $32 at BofA Securities
-
Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
JPMorgan on PTC Therapeutics (PTCT): 'Despite Notable Unknowns for Clinical & Regulatory Outlook, 12-mo PIVOT-HD Update Solidly Encouraging on All Fronts'
-
Citi Reiterates Sell Rating on PTC Therapeutics (PTCT), 'PIVOT-HD Data Update Supportive, But Expectations Measured to this Point'
-
PTC Therapeutics (PTCT) Reports Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects

